Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
SGLT2 Inhibitors Archives
Print | Email | Share | Comments (0)

FDA Approves Invokana, a New Type 2 Drug


Jun 27, 2013

A new, first-in-its-class drug for type 2 diabetes has just been approved by the Food and Drug Administration. Invokana works by blocking re-absorption of glucose by the kidneys and stimulating urination, which removes glucose from the bloodstream.

In the course of nine clinical trials that included over 10,000 patients, the drug improved both A1c and fasting glucose levels. In addition, the drug helps reduce weight and blood pressure. With a regimen that includes diet and exercise, the drug can be taken by itself or in combination with other drugs including insulin, metformin, and others.

Invokana is not intended for those with type1 diabetes, end-stage or severe kidney disease, or people undergoing dialysis. Additional FDA-mandated studies will investigate the drug's effects on the heart, pancreas and other parts of the body; monitoring for malignancies, a bone safety study, and two studies in children.

Invokana, a tablet, is the first of a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. The most common side effects are vaginal yeast and urinary tract infections, thought to be caused by increased urination. As the drug encourages urination, it can also lead to a sudden fall in blood pressure when a patient stands, although this is most common in the first three months of therapy.

The drug is manufactured by Janssen Pharmaceuticals, part of Johnson & Johnson.


Categories: FDA, Invokana, Janssen Pharmaceuticals, SGLT2 Inhibitors, Type 2 Diabetes, Urination



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.